Hoffmann-la Roche Inc.

Alfred Boris

Milan R Uskokovic

John Joseph Partridge

Enrico G Baggiolini

Andrew D Batcho

Richard W Kierstead

Robert W Guthrie

The present invention relates to the method of treating disease states characterized by higher than normal levels of endogenously produced 1.alpha.,25 dihydroxy-cholecalciferol or conditions where there is an increased sensitivity to 1.alpha., 25 dihydroxy-cholecalciferol by administering to an organism suffering from such a disease state a pharmaceutically effective amount of the R or S epimer of 1.alpha.,25,26 trihydroxy-cholecalciferol.

Method of treating disease states by the administration of

The present invention relates to a method of preventing milk fever which comprises administering to a preparturient female ruminant an effective amount of 24,24-difluoro-1.alpha.,25-dihydroxycholecalciferol.

Method of treating milk fever

A method of treating inflammation which comprises topically administering to the affected area a compound of the formula ##STR1## or a pharmaceutically acceptable addition salt thereof, is described.

4-(8-bromodibenz[b,f]oxepin-10-yl)-1,2,3,6-tetrahydro-1-methylpyridine

The invention is directed to a process and intermediates for the preparation of 1.alpha.,25-dihydroxyergocalciferol as well as substantially pure and crystalline 1.alpha.,25-dihydroxyergocolciferol. The end-product 1.alpha.,25-dihydroxyergocalciferol is useful in the treatment of disease states which are characterized by insufficient amounts of 1.alpha., 25-dihydroxycholecalciferol.

Synthesis of 1.alpha.,25-dihydroxyergocalciferol

This invention is directed to methods for and compositions useful in reducing sebum secretion utilizing 1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[.alpha.-methylstyryl]naphthalene as an active ingredient.

Therapeutic compositions for reducing sebum secretion

The invention is directed to a process and intermediates for the preparation of 1.alpha.,25-dihydroxyergocalciferol as well as substantially pure and crystalline 1.alpha.,25-dihydroxyergocolciferol. The end-product 1.alpha.,25-dihydroxyergocalciferol is useful in the treatment of disease states which are characterized by insufficient amounts of 1.alpha.,25-dihydroxycholecalciferol.

The present invention relates to a method of treating osteoporosis by administering to a host suffering from osteoporosis an effective amount of 24,24-difluoro-1.alpha.,25-dihydroxycholecalciferol.

Method of treatment

A class of substituted 2-cycloalkylaminoalkylphenols, preferably D,L-6-(N-.alpha.-pipecolinomethyl)-5-hydroxyindane, enantiomers thereof and acid addition salts thereof have been found to exhibit oral antifertility activity in male aves and mammals. These compounds may therefore be utilized to induce temporary or non-reversible sterility in treated subjects.

Growing community of inventors

Parsippany, NJ, United States of America

Alfred Boris